美泊利单抗治疗慢性阻塞性肺疾病（COPD）：生物治疗的新前沿。
Mepolizumab in Chronic Obstructive Pulmonary Disease (COPD): A new frontier in biologic therapy.
作者信息
Mukesh Arun, Chittoria Konica, Sharma Ankur
机构信息
Department of Anesthesiology and Critical Care, All India Institute of Medical Sciences (AIIMS), Kalyani, India.
Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.
出版信息
Saudi J Anaesth. 2025 Oct-Dec;19(4):604-606. doi: 10.4103/sja.sja_501_25. Epub 2025 Sep 3.
Mepolizumab, a comprehensible monoclonal antibody that inhibits interleukin-5 (IL-5), offers a new therapeutic option for a subset of patients with chronic obstructive pulmonary disease (COPD) marked by eosinophilic inflammation. Despite the success of conventional inhaled therapies, a significant proportion of COPD patients continue to experience exacerbations. This review discusses the mechanism, clinical trials, safety profile, and future potential of mepolizumab, the first and only FDA-approved biologic for COPD.
美泊利珠单抗是一种可理解的抑制白细胞介素-5（IL-5）的单克隆抗体，为一部分以嗜酸性粒细胞炎症为特征的慢性阻塞性肺疾病（COPD）患者提供了一种新的治疗选择。尽管传统吸入疗法取得了成功，但仍有相当一部分COPD患者继续经历病情加重。本综述讨论了美泊利珠单抗的作用机制、临床试验、安全性概况以及未来潜力，它是首个也是唯一一个获美国食品药品监督管理局（FDA）批准用于COPD的生物制剂。
Zotero 插件